目的 探究采用鋁碳酸鎂咀嚼片聯(lián)合雷尼替丁治療胃食管反流病的臨床效果。方法 選取赤峰學(xué)院附屬醫(yī)院2016年7月—2017年7月收治的胃食管反流患者111例，隨機分為對照組（55例）和治療組（56例）。對照組患者口服鹽酸雷尼替丁膠囊，1粒/次，2次/d；治療組在對照組基礎(chǔ)上嚼服鋁碳酸鎂咀嚼片，2片/次，3次/d。兩組患者均經(jīng)過4周治療。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀積分、生活質(zhì)量評分和食管pH值。結(jié)果 治療后，對照組臨床有效率為81.82%，顯著低于治療組的96.43%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者癥狀積分明顯降低，QOL評分明顯升高，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；同時治療組患者的癥狀積分和QOL評分均顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者食管第一、二通道pH<4所占全部時間的百分比均顯著下降，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者上述百分比明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 鋁碳酸鎂聯(lián)合雷尼替丁治療胃食管反流臨床效果明顯，能有效改善患者的病情和生活質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of Hydrotalcite Chewable Tablets combined with ranitidine in treatment of gastroesophageal reflux disease. Methods Patients (111 cases) with gastroesophageal reflux disease in Affiliated Hospital of Chifeng University from July 2016 to July 2017 were randomly divided into control (55 cases) and treatment (56 cases). Patients in the control group were po administered with Ranitidine Hydrochloride Capsules, 1 grain/time, twice daily. Patients in the treatment group were chewing administered with Hydrotalcite Chewable Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the symptom scores, quality of life scores and the time proportion of esophageal pH < 4 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.82%, which was significantly lower than 96.43% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the symptom scores in two groups were significantly decreased, but the QOL scores were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these scores in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the percentage of the total time of pH < 4 in the first and second channel of esophagus in two groups was significantly decreased, and there were differences in the same group (P < 0.05). And the percentage of the total time in the treatment group after treatment were significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Hydrotalcite Chewable Tablets combined with ranitidine can effectively improve the symptom and quality of life in treatment of gastroesophageal reflux disease with significant effect, which has a certain clinical application value.